PharmaKure has received approval from the UK MHRA to begin a Phase 2a study for its drug PK051, intended for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s Disease. PK051 is an oral combined drug that targets the disaggregation of amyloid-β proteins, believed to be the initial event in Alzheimer’s Disease pathology. The study aims to evaluate safety and tolerability and determine an appropriate dose for future efficacy studies. The company’s CEO, Dr Farid Khan, is optimistic about the potential of PK051 and the recent success of a blood test to quantify Alzheimer’s Disease biomarkers, which could enable earlier interventions for better outcomes.
Source link
PharmaKure granted MHRA Clinical Trial Authorisation (CTA) for PK051 for the treatment of mild cognitive impairment due to Alzheimer’s Disease
